Drugs

Themenbereich / / Drugs


Sortiere PresseMitteilungen nach: Titel (A\D) Datum (A\D)

Seiten sind aktuell sortiert nach: Datum (erst neue PresseMitteilungen)

Omni Health, Inc. Releases Letter to Shareholders

MIAMI, FL -- (Marketwired) -- 11/14/17 -- , (OTC PINK: OMHE), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering, today published a letter to its Shareholders. The Letter to Shareholders provides a mid-year corporate update, including recent accomplishments in cannabinoid biotechnology and upcoming milestones, and is as follows:Dear Shareholders,As we move into the second quarter (our financial year ends April 30th), I can honestly say that I have never been more optimistic about our opportunities fo ...

14.11.2017

Cleveland BioLabs Reports Third Quarter 2017 Financial Results and Development Progress

BUFFALO, NY -- (Marketwired) -- 11/14/17 -- (NASDAQ: CBLI) today reported financial results and development progress for the third quarter ended September 30, 2017.Cleveland BioLabs reported a net loss of $(1.3) million, excluding minority interests, for the third quarter of 2017, or $(0.11) per share, compared to a net gain, excluding minority interests, of $1.1 million, or $0.10 per share, for the same period in 2016. The increase in net loss was primarily due to an increase in the non-cash adjustment to our warrant liabilities and decreased revenues and expenses due to the completion of o ...

14.11.2017

Acasti Pharma Reports Second Quarter FY 2018 Financial Results

LAVAL, QUEBEC -- (Marketwired) -- 11/13/17 -- Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced its operating and financial results for the quarter ended September 30, 2017, which is the second quarter of Acasti's fiscal year 2018. All amounts are in Canadian dollars."Acasti met several key milestones in the second quarter, advancing our Phase 3 clinical program ...

13.11.2017

Knight Reports Third Quarter 2017 Results

MONTREAL, QUEBEC -- (Marketwired) -- 11/09/17 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2017. All dollar amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.Q3 2017 HighlightsSubsequent Events"This past quarter our team was focused on advancing our product pipeline and evaluating opportunities to build our portfolio of innovative pharmaceuticals," said Jonathan Ross Good ...

09.11.2017

Acasti Pharma Announces Dariush Mozaffarian, M.D., Dr.P.H. Principal Investigator for CaPre Phase 3 Development Program

LAVAL, QUEBEC -- (Marketwired) -- 11/07/17 -- Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that Dariush Mozaffarian, M.D., Dr.P.H. has agreed to serve as Acasti's principal investigator to oversee the Phase 3 development program of CaPre. Dr. Mozaffarian is a renowned researcher whose widely published work focuses on how diets such as those rich in omega-3s and ...

07.11.2017

Notice of Knight Therapeutics' Third Quarter 2017 Results Conference Call

MONTREAL, QUEBEC -- (Marketwired) -- 11/02/17 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, will release its third quarter 2017 financial results on Thursday, November 9, 2017 prior to the market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.Date: Thursday, November 9, 2017Time: 8:30 a.m. ESTTelephone: 1-877-223-4471 or 647-788-4922Webcast: orThis is a listen-only audio webcast. Media Player is required to lis ...

02.11.2017

Knight Announces Changing of the Finance Guard

MONTREAL, QUEBEC -- (Marketwired) -- 10/10/17 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Jeffrey Kadanoff, CFO is leaving Knight effective October 13, 2017 in order to pursue other opportunities. Mr. Kadanoff served valiantly in this position since Knight became a publicly listed company in February 2014.Effective immediately, Samira Sakhia, President of Knight, will assume the additional responsibility of CFO. Prior to joining Knight, Ms. Sakhia served as CFO of Paladin Labs Inc. for 14 years.Jonatha ...

10.10.2017

Knight Increases Ownership in Crescita

MONTREAL, QUEBEC -- (Marketwired) -- 10/10/17 -- Pursuant to the early warning requirements of National Instrument 62-103, Knight Therapeutics Inc. (TSX: GUD) ("Knight") announced today an increase in its ownership of Crescita Therapeutics Inc. ("Crescita").On October 6, 2017, Knight acquired 566,471 common shares of Crescita, representing 4.0% of the issued and outstanding common shares of Crescita, pursuant to a share transfer agreement entered into on August 31, 2016 by and between Knight and Mr. Gregory Orleski (the "Agreement"). Pursuant to the Agreement, K ...

10.10.2017

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

LAVAL, QUEBEC -- (Marketwired) -- 10/04/17 -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: ACST) announces that in accordance with the terms of its outstanding convertible debentures in the total aggregate principal amount of $2,000,000 issued on February 21, 2017 (the "Debentures"), the Corporation has elected to issue an aggregate of 22,783 common shares to the holders of the Debentures in satisfaction of an aggregate of $40,325.91 of interest payable to the holders of the Debentures, which was earned from July 1, 2017 through ...

04.10.2017

Knight to Present at the 16th Annual CIBC Eastern Institutional Investor Conference in Montreal

MONTREAL, QUEBEC -- (Marketwired) -- 09/21/17 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President, is scheduled to present at the 16th Annual CIBC Eastern Institutional Investor Conference on Wednesday, September 27, 2017 at 3:25 pm ET at Le Centre Sheraton Montreal Hotel in Montreal.About Knight Therapeutics Inc.Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for ...

21.09.2017

Circassia Announces Duaklir(R) Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary Disease

OXFORD, UNITED KINGDOM -- (Marketwired) -- 09/07/17 -- Circassia Pharmaceuticals Plc (LSE: CIR)(LSE: CIR)Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces positive top-line results from the AMPLIFY phase III study of Duaklir®* in chronic obstructive pulmonary disease (COPD), which was conducted by the Company's partner AstraZeneca. Duaklir® is a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and long-acting beta-agonist (L ...

07.09.2017

Acasti Pharma Grants Stock Options

LAVAL, QUEBEC -- (Marketwired) -- 08/31/17 -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ: ACST)(TSX VENTURE: ACST), today announced the grant of an aggregate of 100,000 stock options under the Corporation's Stock Option Plan for its two new directors, Katherine Crewe and Richard P. Schottenfeld, who joined Acasti's Board of Directors at the last Annual and Special Meeting of Shareholders held on August 15, 2017. Subject to the terms and conditions of the plan, these options will vest in equal monthly installments over a period of 36 months and wi ...

31.08.2017

Organigram Launches Company's First Pure CBD Cannabis Oil

MONCTON, NEW BRUNSWICK -- (Marketwired) -- 08/31/17 -- Organigram Holdings Inc. (TSX VENTURE: OGI)(OTCQB: OGRMF) is pleased to announce the release of a new addition to its cannabis oil offerings: a pure CBD edible oil, Shubie. This pure CBD product is a first for Organigram, complementing the company's existing line of medical cannabis oil products.Cannabinoids are the chemical compounds unique to cannabis that act upon the human body's cannabinoid receptors. There are over 80 known cannabinoids present in the cannabis plant, each with varying effects. CBD (or Cannabidiol) is the ...

31.08.2017

Quadron Reports Annual Results for the Year Ended April 30, 2017

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 08/30/17 -- Quadron Cannatech Corporation (the "Company" or "Quadron") (CSE: QCC)(CSE: QCC.CN)(CNSX: QCC) is pleased to report the annual financial and operating results for the year ended April 30, 2017.Year-end Highlights (audited):Subsequent Year End Highlights:"We are very pleased with the results of our first full year of operations - with Quadron's successful CSE listing in late February, and the acquisition of Cybernetic in mid-March, we have built a solid foundation, from design through to production and sa ...

30.08.2017

ICC International Cannabis Corporation Files Financial Results for the Second Quarter Ended June 30, 2017

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 08/29/17 -- ICC International Cannabis Corporation ("ICC" or the "Company") (TSX VENTURE: ICC), a fully licensed producer and distributor of recreational and medicinal cannabis and cannabinoid extracts, is pleased to announce it has filed its interim financial results for the second quarter ended June 30, 2017.The financial statements and management discussion and analysis for the three and six months ended June 30, 2017, will be available on the System for Electronic Document Analysis and Retrieval ("SEDAR") at a ...

30.08.2017

CORRECTION: Maricann Group Inc.

TORONTO, ONTARIO -- (Marketwired) -- 08/22/17 -- In the news release "Maricann Group Inc. Announces Private Placement of $35 Million of Convertible Debenture Units," issued earlier today by Maricann Group Inc. (CSE: MARI), we are advised by the company that the headline should read "up to $35 Million" rather than "$35 Million" and the Maturity Date should read "September 15, 2020" rather than "August 31, 2020," as originally issued, and a disclaimer against dissemination or distribution in the United States has been added, as the original rel ...

22.08.2017

Maricann Group Inc. Announces Acquisition of NanoLeaf Technologies Inc., Appoints New President and Chief Operating Officer

TORONTO, ONTARIO -- (Marketwired) -- 08/22/17 -- Maricann Group Inc. (CSE: MARI)(CSE: MARI.CN)(CNSX: MARI) ("Maricann" or the "Company") announced today that it has entered into an agreement ("Acquisition Agreement") to acquire 100% of the issued and outstanding shares of NanoLeaf Technologies Inc. ("NanoLeaf"), a biotech company possessing licensing rights to a number of globally patented technologies that provide proven pharmaceutical, nutraceutical, cosmetic and functional beverage drug delivery formulations. The transaction is expected to be comple ...

22.08.2017

Maricann Group Inc. Announces Private Placement of $35 Million of Convertible Debenture Units

TORONTO, ONTARIO -- (Marketwired) -- 08/22/17 -- Maricann Group Inc. (CSE: MARI)(CSE: MARI.CN)(CNSX: MARI) ("Maricann" or the "Company") announced today that it has entered into an agreement with Canaccord Genuity Corp., as lead agent on behalf of a syndicate of investment dealers, including Industrial Alliance Securities Inc., Mackie Research Capital Corporation and Sprott Capital Partners (collectively, the "Agents") pursuant to which the Company will issue on a private placement basis up to $35,000,000 aggregate principal amount of convertible debenture units ...

22.08.2017

Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM

MONTREAL, QUEBEC -- (Marketwired) -- 08/16/17 -- Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced that the following individuals were elected as directors of Acasti Pharma Inc. ("Acasti" or the "Corporation") at its Annual and Special Meeting of Shareholders, held in Montreal, Canada on August 15, 2017 (the "AGM"): Janelle D'Alvise, Jean-Marie (John) Canan, Roderick N. Cart ...

17.08.2017

Maricann Group Inc. Enters Into Letter of Intent

TORONTO, ONTARIO -- (Marketwired) -- 08/16/17 -- Maricann Group Inc. (CSE: MARI)(CSE: MARI.CN)(CNSX: MARI) ("Maricann" or the "Company") and a national provider that services pharmacies across Canada (the "Counterparty"), have agreed to a primary collaborative partnership through a joint initiative to create a pharmacy services program that enables pharmacists to counsel and appropriately educate patients in relation to medicinal cannabis.By establishment of this education program for pharmacists to counsel patients, the Counterparty will expand the patient awar ...

16.08.2017


Seite 1 from 65:  1 2  3  4  5  .. » 65





Firmen die firmenpresse.de für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H


I J K L M N O P Q R S T U V W X Y Z